These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25105536)

  • 1. Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia.
    Cummins KD; Jane SM; Ninkovic S; Bazargan A; Filshie R; Sutrave G; Hertzberg M; Scott A; Lane S; Yannakou CK; Ritchie D; D'Rozario J; Black J; Bavishi K; Wei A
    Blood Cancer J; 2014 Aug; 4(8):e237. PubMed ID: 25105536
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
    Mohan BP; How GF; Loh Y; Linn YC
    Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
    Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
    Osone S; Imamura T; Kanayama T; Tsuma Y; Kawashima-Goto S; Nakatani T; Sugimoto A; Takai A; Miyachi M; Tamura S; Ishida H; Hosoi H
    J Pediatr Hematol Oncol; 2017 May; 39(4):e199-e202. PubMed ID: 27571118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
    Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; El-Jawahri A; Fathi AT; Ho VT; Joyce A; McAfee S; Rudek M; Rajkhowa T; Verselis S; Antin JH; Spitzer TR; Levis M; Soiffer R
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2042-8. PubMed ID: 25239228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
    Fontanelli G; Rocco M; Caracciolo F; Benedetti E; Buda G; Orciuolo E; Carulli G; Galimberti S; Azzarà A; Petrini M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e13-7. PubMed ID: 24144836
    [No Abstract]   [Full Text] [Related]  

  • 7. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
    Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
    J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
    [No Abstract]   [Full Text] [Related]  

  • 9. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
    Zhang Y; Xuan L; Fan Z; Huang F; Jiang Q; Xu N; Gao Y; Sun J; Liu Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):292-6. PubMed ID: 27093991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
    Sid S; Rey J; Charbonnier A; D'Incan E; Mohty B; Blaise D; Vey N
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):241-242. PubMed ID: 28196687
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
    Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
    Giri S; Hamdeh S; Bhatt VR; Schwarz JK
    J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
    Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
    Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
    Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
    Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
    Liegel J; Courville E; Sachs Z; Ustun C
    Haematologica; 2014 Nov; 99(11):e222-4. PubMed ID: 25015937
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
    Jiang ZH; Feng FE; Lin XQ; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):736. PubMed ID: 23978034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.